10-K: Disc Medicine Faces Bitopertin Setback, Boosts Cash Reserves

Disc Medicine received a Complete Response Letter from the FDA for bitopertin's accelerated approval in EPP and XLP, while reporting increased net losses and a strong cash position.

Summary

• Disc Medicine, a clinical-stage biopharmaceutical company, focuses on novel treatments for serious hematologic diseases by modifying heme biosynthesis and iron homeostasis pathways.
• The FDA issued a Complete Response Letter (CRL) for bitopertin's accelerated approval in Erythropoietic Protoporphyria (EPP) and X-linked Protoporphyria (XLP), citing insufficient association between PPIX reduction and sunlight exposure endpoints, despite acknowledging PPIX lowering.
• The company plans to request a Type A meeting with the FDA and expects topline data from the ongoing Phase 3 APOLLO trial in Q4 2026 to support a potential traditional approval.
• Net losses significantly increased to $212.2 million for the year ended December 31, 2025, up from $109.4 million in 2024, primarily due to increased research and development expenses.
• Research and development expenses rose by $74.0 million to $170.6 million in 2025, driven by a $10.0 million milestone payment for the APOLLO trial and increased costs for APOLLO and HELIOS studies.
• Selling, general and administrative expenses increased by $32.3 million to $65.4 million in 2025, due to higher headcount and commercialization capability development.
• The company completed an underwritten offering in October 2025, raising $211.0 million in net proceeds, contributing to a cash, cash equivalents, and marketable securities balance of $791.2 million as of December 31, 2025.
• Initial data from the RALLY-MF Phase 2 trial of DISC-0974 in anemia of myelofibrosis showed meaningful overall anemia responses across patient subgroups, with topline data expected in H2 2026.
• Phase 1 clinical trial of DISC-3405 in healthy volunteers demonstrated dose-related increases in serum hepcidin and reductions in serum iron, with initial data from the RESTORE-PV Phase 2 trial and a Phase 1b SCD trial expected in H2 2026.
• The material weakness in internal controls over financial reporting identified in 2024 related to ITGCs has been fully remediated as of December 31, 2025.

Sentiment

Score: 4

Explanation: StockSavvy.ai views this filing with cautious optimism. While the FDA's CRL for bitopertin is a significant setback, the company's strong cash position and continued progress across a diversified pipeline, particularly with positive initial data for DISC-0974, provide a foundation for future value creation despite increased losses.

Positives

• Initial data from the RALLY-MF Phase 2 trial of DISC-0974 in anemia of myelofibrosis demonstrated meaningful overall anemia responses across all patient subgroups, regardless of baseline transfusion status and independent of concomitant JAK inhibitor therapy use.
• DISC-0974 was generally well-tolerated in the RALLY-MF trial, with diarrhea and urinary tract infections being the only related adverse events reported in two or more subjects.
• Phase 1 clinical trial of DISC-3405 in healthy adult volunteers showed an acceptable tolerability profile and evidence of target engagement, including dose-related increases in serum hepcidin and corresponding reductions in serum iron.
• The company's cash, cash equivalents, and marketable securities totaled $791.2 million as of December 31, 2025, which is believed to be sufficient to fund operations and debt service obligations into 2029.
• Successfully raised $211.0 million in net proceeds from an underwritten offering in October 2025, strengthening the financial position.
• The material weakness in internal controls over financial reporting identified in 2024 has been fully remediated as of December 31, 2025.
• Bitopertin received a Commissioners National Priority Voucher (CNPV) from the FDA in October 2025, designed to accelerate development and review for national health priorities.

Negatives

• The FDA issued a Complete Response Letter (CRL) for bitopertin's New Drug Application (NDA) for accelerated approval in EPP and XLP, concluding that trials did not show evidence of association between PPIX reduction and sunlight exposure-based endpoints.
• Net losses significantly increased to $212.2 million for the year ended December 31, 2025, compared to $109.4 million in 2024.
• Research and development expenses increased substantially by $74.0 million to $170.6 million in 2025.
• Selling, general and administrative expenses increased by $32.3 million to $65.4 million in 2025.
• The FDA's CRL for bitopertin indicates that traditional approval would require evidence of clinical benefit from an additional trial, such as the ongoing APOLLO trial, delaying potential market entry.
• DISC-0974 in non-dialysis dependent chronic kidney disease (NDD-CKD) showed variable effects on hemoglobin, with meaningful increases observed only in a subset of patients, leading to an assessment of options for the program.

Risks

• Limited operating history makes it difficult to evaluate future viability and success in developing, obtaining regulatory approvals, manufacturing, and commercializing products.
• Significant net losses are anticipated to continue for the foreseeable future, with no products approved for commercial sale and no revenue from product sales to date.
• Substantial additional funding may be required, and inability to raise capital on acceptable terms could force delays, reductions, or elimination of product development or commercialization efforts.
• Product candidates have not yet progressed through a Phase 3 clinical trial, and preclinical programs may never advance to clinical development.
• Focus on novel therapeutics for rare hematologic diseases, with little clinical experience and new endpoints, may lead to regulatory authorities not considering trial endpoints clinically meaningful.
• Interim, top-line, initial, and preliminary data from clinical trials are subject to change and may differ materially from final data.
• Delays or difficulties in patient enrollment in clinical trials could delay or prevent regulatory approvals.
• Clinical trials may reveal significant adverse events not seen in prior studies, resulting in safety profiles that inhibit regulatory approval or market acceptance.
• Modulating pathways without approved therapies may lead to greater R&D expenses, regulatory issues, or discovery of unknown adverse effects.
• FDA or comparable foreign regulatory authorities may not accept data from clinical trials conducted outside the United States.
• Substantial competition from pharmaceutical and biotechnology companies with greater resources and expertise.
• Market opportunities for product candidates may be smaller than estimated, or regulatory approval may be based on a narrower patient population definition.
• Failure of current or future product candidates to achieve broad market acceptance could limit revenue and prevent profitability.
• Reliance on third parties (CROs, CDMOs) to conduct clinical trials and manufacturing increases risks of delays, insufficient quantities, or non-compliance.
• Failure to realize anticipated benefits from collaborations (e.g., Mabwell, NIH) or inability to establish new collaborations on commercially reasonable terms.
• Inability to obtain and maintain patent and other intellectual property protection, or if the scope is not broad enough, could allow competitors to commercialize similar drugs.
• Changes in tax law, including the One Big Beautiful Bill Act (OBBBA), could adversely affect the company or investors.
• Utilization of net operating loss (NOL) carryforwards and research and development tax credits may be limited by ownership changes under Section 382 of the Code.
• Exposure to U.S. and foreign anti-corruption, anti-money laundering, export control, sanctions, and other trade laws and regulations, with potential for serious consequences for violations.
• Adverse developments in the financial services industry could affect funding sources and financial condition.
• Significant political, trade, or regulatory developments, unfavorable global economic conditions, and other uncontrollable circumstances could materially affect business.
• Volatility in the market price of common stock due to various factors, including clinical trial results, regulatory actions, and competitive landscape.
• Increased costs and demands on management due to compliance with laws and regulations affecting public companies.
• Potential for cyberattacks or security compromises leading to disclosure of confidential information, reputational harm, and significant financial and legal exposure.
• Difficulties in managing growth as development and regulatory capabilities expand, and potential implementation of sales, marketing, and distribution capabilities.

Future Outlook

The company expects to report topline data from the APOLLO Phase 3 trial for bitopertin in EPP and XLP in the fourth quarter of 2026, after which it plans to submit a response to the FDA's Complete Response Letter. Topline data from the RALLY-MF Phase 2 trial of DISC-0974 in anemia of MF is expected in the second half of 2026, which, if positive, is anticipated to support discussions with regulatory agencies on the potential regulatory path. Initial data from the RESTORE-PV Phase 2 trial of DISC-3405 in PV and the Phase 1b trial in SCD are also expected in the second half of 2026. The company plans to explore additional indications for its product candidates and continue pipeline expansion through internal research and business development. The current cash position is projected to fund operations into 2029.

Management Comments

• We plan to request a Type A meeting to review our approach with the FDA regarding bitopertin's path to traditional approval.
• We expect to report topline data from APOLLO in the fourth quarter of 2026, following which we plan to submit a response to the CRL.
• Topline data from the RALLY-MF Phase 2 trial is expected in the second half of 2026, which, if positive, is expected to support discussions with regulatory agencies on the potential regulatory path for DISC-0974 in anemia of MF.
• We expect to report initial data from our RESTORE-PV trial in the second half of 2026.
• We also initiated a Phase 1b, open-label clinical trial of DISC-3405 in patients with SCD in October 2025, with initial data expected in the second half of 2026, and plan to explore the role of therapeutic iron restriction in other indications.
• We believe that our cash, cash equivalents and marketable securities will be sufficient to fund our current operating and capital expenditure plans and our debt service obligations into 2029.

Industry Context

StockSavvy.ai notes that Disc Medicine operates in the highly competitive and capital-intensive biopharmaceutical industry, particularly within hematologic diseases. The FDA's CRL for bitopertin highlights the significant regulatory hurdles and the challenge of establishing clear clinical benefit for novel endpoints, even with strong mechanistic plausibility. This outcome underscores the inherent risks in drug development, especially for rare diseases where clinical trial design and patient enrollment can be particularly complex. The company's diversified pipeline, with multiple candidates targeting different hematologic conditions, is a strategic move to mitigate single-asset risk. The strong cash position, bolstered by recent offerings, provides a crucial runway for continued R&D, which is essential given the extended timelines implied by the bitopertin CRL. Competitors like Clinuvel (Scenesse) and Mitsubishi Tanabe Pharma Corporation (dersimelagon) in EPP, and various companies developing erythroid maturation agents or JAK2 inhibitors for MF, indicate a crowded landscape where differentiation and successful clinical execution are paramount.

Comparison to Industry Standards

• In EPP/XLP, bitopertin's development faces competition from melanocortin-1 receptor agonists like afamelanotide (Scenesse by Clinuvel), which was approved by the FDA in 2019 and increased median pain-free hours in daylight from 40.5 to 64.1 over 180 days in a pivotal trial. Dersimelagon (Mitsubishi Tanabe Pharma Corporation), another oral MC1R agonist, recently completed a Phase 3 trial.
• For anemia of Myelofibrosis, there are no approved therapies, but off-label use of ESAs (e.g., Procrit by Janssen, Epogen/Aranesp by Amgen, Mircera by Roche), corticosteroids, and androgens (e.g., danazol) are common. Newer erythroid maturation agents like luspatercept (Bristol-Myers Squibb, recently completed Phase 3) and KER-050 (Keros Therapeutics, in Phase 2) are in development. Ojaara (momelotinib by GlaxoSmithKline), a JAK2 kinase inhibitor, was approved to treat myelofibrosis patients with anemia.
• In Polycythemia Vera, rusfertide (Protagonist Therapeutics, Inc.), an investigational hepcidin mimetic peptide, recently completed a Phase 3 clinical trial, demonstrating iron restriction as a viable approach to disease control, similar to DISC-3405's mechanism.
• For Sickle Cell Disease, recently approved gene therapies include Casgevy (Vertex Pharmaceuticals) and Lyfgenia (Bluebird Bio). Other treatments include hydroxyurea, L-glutamine, Adakveo (Novartis) for vasoocclusive crises, and Endari (Emmaus Medical Inc) for acute complications, indicating a crowded competitive pipeline.

Corporate Governance

Legal Proceedings

• The company is not currently a party to any material legal proceedings.

Related Party Transactions

• Certain existing investors participated in the company's underwritten offerings in October 2025, January 2025, June 2024, June 2023, and February 2023.
• In March 2023, the company executed a promissory note for $0.5 million from an existing investor, which was repaid four days later with a de minimis amount of interest expense.

Stakeholder Impact

• **Shareholders:** The FDA's CRL for bitopertin introduces significant uncertainty and delays for a key pipeline asset, potentially impacting future revenue and stock performance. However, successful capital raises and a strong cash position provide financial stability and a runway for continued development across the pipeline.
• **Patients (EPP/XLP):** The delay in bitopertin's approval means patients will have to wait longer for a potential disease-modifying treatment. The need for additional clinical data underscores the FDA's commitment to robust evidence of clinical benefit.
• **Employees:** Continued R&D investment and pipeline expansion suggest ongoing employment opportunities, but the regulatory setback for bitopertin could impact morale or strategic focus. The remediation of internal control weaknesses is positive for operational stability.
• **Regulatory Authorities:** The FDA's decision reinforces its rigorous standards for accelerated approval, particularly regarding the correlation between surrogate endpoints and clinical benefit, setting a precedent for future submissions in rare diseases.

Next Steps

• Request a Type A meeting with the FDA to review the approach for bitopertin's potential traditional approval.
• Report topline data from the APOLLO Phase 3 trial for bitopertin in EPP and XLP in the fourth quarter of 2026.
• Submit a response to the FDA's Complete Response Letter for bitopertin following receipt of APOLLO topline data.
• Report topline data from the RALLY-MF Phase 2 trial of DISC-0974 in anemia of MF in the second half of 2026.
• Initiate a Phase 2 clinical trial of DISC-0974 in patients with IBD and anemia in the first quarter of 2026.
• Plan exploratory studies for DISC-0974 in additional patient populations with anemia of chronic disease.
• Report initial data from the RESTORE-PV Phase 2 clinical trial of DISC-3405 in PV in the second half of 2026.
• Report initial data from the Phase 1b, open-label clinical trial of DISC-3405 in patients with SCD in the second half of 2026.
• Explore the role of therapeutic iron restriction with DISC-3405 in other indications.
• Continue IND-enabling activities for the preclinical product candidate DISC-0998.
• Continue to build the pipeline through internal research or business development, including next-generation programs and molecules targeting other red blood cell pathways.
• Opportunistically evaluate strategic collaborations to maximize the value of product candidates and preclinical programs.

Key Dates

Recommendation

The FDA's Complete Response Letter for bitopertin's accelerated approval is a significant negative, introducing substantial delays and uncertainty for a lead product candidate. This setback will likely weigh on the stock. However, the company's robust cash position of $791.2 million, sufficient to fund operations into 2029, provides a strong financial buffer. Furthermore, positive initial data for DISC-0974 in anemia of myelofibrosis and ongoing development of DISC-3405 offer future growth potential. Given the mixed news, with a major setback balanced by strong liquidity and other promising pipeline assets, a 'hold' recommendation is appropriate. Investors should await further clarity on bitopertin's regulatory path and the progression of other clinical programs.

Keywords

Hematologic Diseases, Biopharmaceutical, Clinical-stage, Bitopertin, Erythropoietic Protoporphyria, X-linked Protoporphyria, DISC-0974, Anemia of Myelofibrosis, DISC-3405, Polycythemia Vera, Sickle Cell Disease, Heme Biosynthesis, Iron Homeostasis, FDA CRL, Phase 3 Clinical Trial, Drug Development, Orphan Drug, Rare Pediatric Disease, Biologics, Monoclonal Antibody, SEC Filing, Financial Performance, Research and Development, Capital Raise